New Approaches, New Hope

Learn More About OncoSec

LEARN MORE

TAVO™

Investigational Intratumoral Cancer Immunotherapy

LEARN MORE

OncoSec Announces Strategic Collaboration

OncoSec to receive a $30M investment at a premium to market by China Grand Pharmaceutical (CGP). OncoSec grants CGP exclusive license to TAVO™ in Greater China and 35 other Asian Countries.

LEARN MORE

News & Events

OncoSec Corporate Presentation

CEO Letter

OncoSec Presents Immunological Data Associated with Positive Tumor Response from TAVO™ KEYNOTE Studies Evaluating Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting

November 12, 2019

OncoSec to Present TAVO™ Immune Biomarker Data Associated with Positive Clinical Response from Ongoing KEYNOTE Studies at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting

November 05, 2019

Fran’s Story

Reclaiming Independence from Melanoma

“I was headed down a one-way street with dead end.”

Watch Video

Designed to Arm the Immune System to Fight Cancer

We are investigating the potential for our lead product candidate, TAVO, through the intratumoral administration of IL-12, to stimulate systemic immune response and to become an innovative and potentially transformative therapy option for the treatment of cancer.